[{"address1": "1300 South El Camino Real", "address2": "Suite 400", "city": "San Mateo", "state": "CA", "zip": "94402", "country": "United States", "phone": "(650) 781-5200", "website": "https://www.kronosbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Dr. Norbert W. Bischofberger Ph.D.", "age": 67, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 912200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 46, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David M. Tanen J.D.", "age": 52, "title": "Secretary & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Deborah A. Knobelman Ph.D.", "age": 49, "title": "COO & CFO", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Margaux  Bennett Ph.D.", "title": "Vice President of Corporate Development & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Allison  Frisbee J.D.", "age": 40, "title": "Senior Vice President of Corporate Operations & Legal", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles  Lin Ph.D.", "age": 38, "title": "Senior Vice President of Research & Development", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elizabeth A. Olek D.O., M.P.H.", "age": 58, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wes  Trotter Ph.D.", "title": "Senior Vice President of Drug Discovery & Pharmaceutical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.34, "open": 1.34, "dayLow": 1.3033, "dayHigh": 1.37, "regularMarketPreviousClose": 1.34, "regularMarketOpen": 1.34, "regularMarketDayLow": 1.3033, "regularMarketDayHigh": 1.37, "beta": 1.894, "forwardPE": -0.88000005, "volume": 60924, "regularMarketVolume": 60924, "averageVolume": 433396, "averageVolume10days": 188870, "averageDailyVolume10Day": 188870, "bid": 1.31, "ask": 1.34, "bidSize": 300, "askSize": 200, "marketCap": 79324608, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 2.09, "priceToSalesTrailing12Months": 10.455333, "fiftyDayAverage": 1.08336, "twoHundredDayAverage": 1.101865, "currency": "USD", "enterpriseValue": -45185380, "floatShares": 42722317, "sharesOutstanding": 60094400, "sharesShort": 779526, "sharesShortPriorMonth": 723505, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.012999999, "heldPercentInsiders": 0.26974002, "heldPercentInstitutions": 0.36216, "shortRatio": 2.72, "shortPercentOfFloat": 0.0171, "bookValue": 2.279, "priceToBook": 0.5792014, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -116393000, "trailingEps": -1.99, "forwardEps": -1.5, "enterpriseToRevenue": -5.956, "enterpriseToEbitda": 0.427, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KRON", "underlyingSymbol": "KRON", "shortName": "Kronos Bio, Inc.", "longName": "Kronos Bio, Inc.", "firstTradeDateEpochUtc": 1602250200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6f8f728e-bb6c-3b57-873b-3a705e9ece7a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.32, "targetHighPrice": 6.0, "targetLowPrice": 2.25, "targetMeanPrice": 4.13, "targetMedianPrice": 4.13, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 151984000, "totalCashPerShare": 2.529, "ebitda": -105890000, "totalDebt": 27474000, "quickRatio": 7.986, "currentRatio": 8.321, "totalRevenue": 7587000, "debtToEquity": 20.059, "revenuePerShare": 0.13, "returnOnAssets": -0.28583, "returnOnEquity": -0.64204, "freeCashflow": -46757376, "operatingCashflow": -96534000, "revenueGrowth": 1.064, "grossMargins": 1.0, "operatingMargins": -7.62222, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-29"}]